This site is intended for health professionals only

Wednesday 24 April 2019
Share |

Topic: *** Editor's Pick

April 23, 2019
Scientists from the Cancer Research UK Manchester Institute at The University of Manchester showed that a small volume of blood can contain up-to-date genetic information about a patient's cancer to inform treatment choices

Scientists could help match cancer patients with no other treatment options to clinical trials with experimental medicines, by analysing the genetic faults in a sample of their blood, according to research published in Nature Medicine.

The researchers, funded by Cancer Research UK, The Christie Charity, AstraZeneca and the NIHR Manchester Biomedical Research Centre (BRC), demonstrated in their feasibility study that a blood test can be carried out and analysed in a timeframe that can help clinicians select a matched, targeted treatment.

April 15, 2019
Identification of the allergic triggers of rhinitis is crucial in order to implement adequate avoidance measures in both atopic and non-atopic patients; moreover, this identification can help administer specific therapies, such as allergen immunotherapy
Rhinitis is an inflammatory disorder of the nasal mucosa clinically defined by two or more symptoms of nasal itching, sneezing, anterior or posterior rhinorrhoea, and nasal blockage.1
 
April 15, 2019
New research suggests that B cells gone bad could be the culprit in rheumatoid arthritis
A comprehensive profile of B cells in rheumatoid arthritis (RA), a first of its kind study, has been published in Arthritis & Rheumatology.1 
 
April 15, 2019
This collaboration is expected to take several forms, including joint design and implementation of clinical research, working meetings at scientific conferences, cross-entity working groups with diverse functional group participation and clinical trial innovations
The US-based Antibacterial Resistance Leadership Group (ARLG), part of the Duke Clinical Research Institute (DCRI) and the University Medical Center (UMC) Utrecht, the managing entity of the COMBACTE (Combatting Bacterial Resistance in Europe) consortium, will work together to solidify a comprehensive global community to combat the threat of antibiotic resistance around the world.
 
April 12, 2019
Research conducted at the School of Pharmacy and Pharmaceutical Sciences at Cardiff University, UK aimed to understand the development of bacterial resistance to four different topical antibiotics commonly used in some OTC sore throat medicines
Research presented at the 2019 European Congress of Clinical Microbiology & Infectious Diseases shows that the inappropriate of use of antibiotics legitimately available in over-the-counter (OTC) throat medications could be contributing to antibiotic resistance, thereby going against World Health Organization (WHO) goals.
 
April 12, 2019
Scientists could be a step closer to providing more precise pollen forecasts to the 25% of the UK population who live with either asthma or hay fever
A study published in Nature Ecology & Evolution has shown that it is not just the overall 'load' of grass pollen in the air that could cause those particularly bad days for asthma and hay fever sufferers.1 Days that see increased asthma attacks or intense hay fever could be related to the release of pollen from particular grass species.
 
April 12, 2019
An eight-year hunt for the cells that drive the extreme childhood food allergy eosinophilic oesophagitis has identified a potential new way to treat the disease while also raising questions about a dietary supplement taken to reduce bowel inflammation
An eight-year hunt for the cells that drive the extreme childhood food allergy eosinophilic esophagitis (EoE) has identified a potential new way to treat the disease while also raising questions about a dietary supplement often taken to reduce bowel inflammation.
 
The study, led by experts at Cincinnati Children's Hospital Medical Center, is posted online in the Journal of Clinical Investigation1 and will be published in print in May. 
 
April 12, 2019
Improving results for patients by realising the transformational potential of Real World Data
HONEUR (Haematology Outcomes Network in Europe) is a Janssen-led initiative and part of the company’s overall commitment to creating better outcomes for patients – in this case, by harnessing the full potential of Real World Data and the insights it can provide. 
 
April 12, 2019
Researchers have effectively prevented the binding of peanut allergens with IgE to suppress the allergic reaction to peanuts using a first-in-class design of allergen-specific inhibitors
In a study published in the Proceedings of the National Academy of Sciences, researchers at the University of Notre Dame in the US have effectively prevented the binding of peanut allergens with IgE to suppress the allergic reaction to peanuts using a first-in-class design of allergen-specific inhibitors.
 
April 10, 2019
European health insurance cards (EHIC) may no longer be valid in the event of a no-deal Brexit, the Department of Health and Social Care has said.

European health insurance cards (EHIC) may no longer be valid in the event of a

April 10, 2019
In oncology, in particular, where there are often no alternatives to these medicines, shortages pose a threat to patient safety as they reduce adherence to therapy and limit the ability of physicians to provide effective treatment regimens

Shortages of essential cancer medicines have a direct impact on patient care across Europe.

To ensure that this issue remains a top priority on the EU policy agenda, ESMO collaborated with the European Parliament to organise a cross-partisan event entitled “Shortages of Inexpensive, Essential Medicines: Calling for Tangible Political Commitments in the EU”.1

April 10, 2019
Those who qualified in the European Union (EU) can continue to practise in the UK after Brexit, even in a no-deal scenario, the Government has confirmed.

Healthcare professionals who qualified in the European Union (EU) can continue to practise in the UK after Brexit, e

April 10, 2019
Modelling study shows that up to 43% of the world’s future hepatitis C infections could be prevented if transmission among people who inject drugs was reduced

Stepping up efforts to prevent transmission of hepatitis C among people who inject drugs, could reduce future infections by 43% globally, according to a study by researchers at the University of Bristol published in the Lancet Gastroenterology and Hepatology.1

April 10, 2019
First PARP inhibitor approved in the EU for patients with this difficult-to-treat disease and third EU approval for Lynparza

The European Commission has approved Lynparza (olaparib) as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations (gBRCAm), and who have human epidermal growth factor receptor 2 (HER2)-negative locally-advanced or metastatic breast cancer.

April 9, 2019
NHS England has said it is going to ‘formally request’ that the Government bans GPs from prescribing homeopathy.

NHS England has said it is going to "formally request" that the Government bans GPs from prescribing homeo

April 8, 2019
The European Centre for Disease Prevention and Control estimates that a severe pandemic could infect up to a quarter of the population of the European Union, with many millions of cases and tens of thousands of deaths
Seqirus has signed contracts with the European Commission and 15 European Union Member States to supply pandemic influenza vaccines as part of the response to a pandemic emergency. 
 
It is the first influenza vaccine manufacturer to sign pandemic contracts under the EU joint procurement framework.
 
April 8, 2019
A clinical review published in the BMJ provides new interim advice for doctors and clinicians in prescribing cannabis-based products and cannabinoids to treat certain conditions
Since a policy change in November 2018, specialist doctors registered with the General Medical Council (GMC), have been permitted to prescribe new medicines which derive from cannabis. Yet, research into these products has, to date, been limited creating an 'information vacuum' about these medicines, their benefits or harms.
 
April 8, 2019
Research on the X chromosome has pointed to an abnormality in the immune system's T cells as a possible factor in lupus and other autoimmune diseases
Eighty-five percent of people with lupus are female, and their second X chromosome seems partly to blame. 
 
According to a new study by researchers at the University of Pennsylvania, females with lupus do not fully "silence" their second X chromosome in the immune system's T cells, leading to abnormal expression of genes linked to that chromosome.
 
April 5, 2019
An international research team has found that patients with the lung disease bronchiectasis also often display sensitivity to airborne allergens, and has highlighted the particular role that fungi appear to play
An international research team from Singapore has found that patients with the lung disease bronchiectasis also often display sensitivity to airborne allergens, and has highlighted the particular role that fungi appear to play.
 
Their discovery suggests that bronchiectasis patients should be examined for a range of allergies, since the treatment for allergies already exists and controlling them could prevent the bronchiectasis from worsening.
 
April 5, 2019
Immediate first-line access to this combination could be a treatment option for up to 1700 advanced kidney cancer patients in England
Bristol-Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending the combination of Opdivo® (nivolumab) plus Yervoy® (ipilimumab) to treat NHS patients in England with renal cell carcinoma (RCC). 
 
April 5, 2019
The UK medicines watchdog has issued guidance on fluoroquinolone antibiotics following some reports of ‘potentially irreversible’ side effects affecting multiple systems, organ classes and senses

The UK medicines watchdog has issued guidance on fluoroquinolone antibiotics following some reports of ‘potentially irreversible’ side effects affecting multiple systems, organ classes and senses.

The Medicines and Healthcare Regulatory Authority (MHRA) cautioned healthcare professionals on 21 March against prescribing the drug and to advise patients to stop taking it if they experienced side effects including muscle pain and peripheral neuropathy.

April 4, 2019
Different models should be evaluated to overcome specific transition items such as barriers to successful outcomes, and poor compliance and complications, in order to improve quality of life for the future adult
Transition is defined as the purposeful, planned movement of adolescents and young adults from a child-centred to adult-oriented health care system.1
 
April 2, 2019
The SLE populations of the pivotal BLISS-52 and BLISS-76 trials constitute large patient cohorts, ideal for post-hoc survey to better understand the disease itself, and the effects of belimumab treatment
The treatment of systemic lupus erythematosus (SLE) has traditionally been non-specific, comprising glucocorticoids, non-steroidal anti-inflammatory drugs and broad immunosuppressive agents.
 
The monoclonal antibody belimumab towards the soluble counterpart of the B cell activating factor belonging to the tumour necrosis factor family (BAFF), also known as B lymphocyte stimulator (BLyS), is the only targeted therapy approved by regulatory agencies for SLE, and has been available for use since 2011.1
March 28, 2019
New immunotherapy drug targets for cancer will be progressed through a multimillion-pound drug discovery alliance between Cancer Research UK, LifeArc and Ono Pharmaceutical Co Ltd
A multi-year partnership brings together Cancer Research UK’s network of world-leading scientists and drug discovery expertise, LifeArc’s renowned therapeutic antibody engineering and development expertise, and Ono’s considerable track record in developing cancer immunotherapies.